Albany, NY -- (SBWire) -- 09/04/2019 --Critical Limb Ischemia Market Insights, Epidemiology and Market Forecast-2028

1. Critical Limb Ischemia prevalence is 1.3 % in the adult US population.
2. The mean age of Critical Limb Ischemia patients is higher than that of non- Critical Limb Ischemia patients (75 years) but the range is wide (35–100 years).
3. Critical limb ischemia may be considered as the most severe pattern of peripheral artery disease (PAD), is associated with a high risk of major amputation, cardiovascular events and death.

DelveInsight launched a new report on Critical Limb Ischemia Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Critical Limb Ischemia market report covers a descriptive overview and comprehensive insight of the Critical Limb Ischemia epidemiology and Critical Limb Ischemia market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Critical Limb Ischemia market report provides insights on the current and emerging therapies.
3. Critical Limb Ischemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Critical Limb Ischemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Critical Limb Ischemia market.

Request for sample pages

"Acute Critical Limb Ischemia prevalence is 9–16 cases per 100,000 persons per year for the lower extremity and around 1–3 cases per 100,000 persons per year for the upper extremity."

Critical Limb Ischemia treatment depends upon the location of the ischemia and its severity. However, for all forms of ischemia, controlling risk factors, especially smoking cessation, is essential. It may prevent the progression of ischemia and save a life. Critical Limb Ischemia treatment is focused upon getting more blood supply to the area of ischemia. This can be accomplished in several ways: Medications, Exercise, and Surgery or Endovascular Procedures.
Several medications may be prescribed to prevent further progression of the disease and to reduce the effect of contributing factors such as high blood pressure, high cholesterol, and diabetes, and most certainly to reduce the pain. Medications that prevent clotting or fight infections may also be prescribed. This approach should include complete smoking cessation, high-dose statin, antiplatelet, and antihypertensive therapy to reduce major adverse cardiovascular events. If one experiences claudication in the legs or angina in the heart, a supervised exercise routine may be prescribed. In many cases, an endovascular procedure may be performed within the artery using clot-busting drugs to dissolve clots (thrombolysis). These treatments are the least invasive and inserting a catheter into the artery allows access to the diseased portion of the artery. Angioplasty may be used to open blockages by placing small balloons introduced with a catheter into an artery. If the arterial blockages are not favorable for endovascular therapy, surgery is often recommended. This involves removing or bypassing the arterial disease with either a vein from the patient or a synthetic graft.

The launch of the emerging therapies is expected to significantly impact Critical Limb Ischemia treatment scenario in the upcoming years:-
Drugs covered
1. PLX-PAD
2. Rexmyelocel-T
3. CLBS12
And many others

The key players in Critical Limb Ischemia market are:
1. Pluristem Ltd.
2. Rexgenero Ltd.
3. Caladrius Biosciences
And many others

Table of contents

1. Report Introduction
2. Critical Limb Ischemia Market Overview at a Glance
3. Critical Limb Ischemia Disease Background and Overview
4. Critical Limb Ischemia Epidemiology and Patient Population
5. Critical Limb Ischemia Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Critical Limb Ischemia Treatment & Medical Practices
7. Key Emerging Therapies
7.1. PLX-PAD: Pluristem Ltd.
7.2. Rexmyelocel-T: Rexgenero Limited
7.3. CLBS12: Caladrius Biosciences
8. Critical Limb Ischemia Market Size
9. 7MM Critical Limb Ischemia: Country-Wise Market Analysis
9.1. United States
9.2. Germany
9.3. France
9.4. United Kingdom
9.5. Spain
9.6. Italy
9.7. Japan
10. Market Drivers
11. Market Barriers
12. Appendix
13. Critical Limb Ischemia Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight